GB202101125D0 - Antibodies and uses thereof - Google Patents

Antibodies and uses thereof

Info

Publication number
GB202101125D0
GB202101125D0 GBGB2101125.9A GB202101125A GB202101125D0 GB 202101125 D0 GB202101125 D0 GB 202101125D0 GB 202101125 A GB202101125 A GB 202101125A GB 202101125 D0 GB202101125 D0 GB 202101125D0
Authority
GB
United Kingdom
Prior art keywords
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2101125.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymab Ltd
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymab Ltd filed Critical Kymab Ltd
Priority to GBGB2101125.9A priority Critical patent/GB202101125D0/en
Publication of GB202101125D0 publication Critical patent/GB202101125D0/en
Priority to PCT/EP2022/051959 priority patent/WO2022162097A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB2101125.9A 2021-01-27 2021-01-27 Antibodies and uses thereof Ceased GB202101125D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2101125.9A GB202101125D0 (en) 2021-01-27 2021-01-27 Antibodies and uses thereof
PCT/EP2022/051959 WO2022162097A2 (en) 2021-01-27 2022-01-27 Antibodies and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2101125.9A GB202101125D0 (en) 2021-01-27 2021-01-27 Antibodies and uses thereof

Publications (1)

Publication Number Publication Date
GB202101125D0 true GB202101125D0 (en) 2021-03-10

Family

ID=74858954

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2101125.9A Ceased GB202101125D0 (en) 2021-01-27 2021-01-27 Antibodies and uses thereof

Country Status (2)

Country Link
GB (1) GB202101125D0 (en)
WO (1) WO2022162097A2 (en)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5290540A (en) 1991-05-01 1994-03-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for treating infectious respiratory diseases
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5985320A (en) 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
PT954282E (en) 1997-01-16 2005-06-30 Massachusetts Inst Technology PREPARATION OF PARTICLES FOR INHALATION
EP1089712B1 (en) 1998-06-24 2003-05-02 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
AT503889B1 (en) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F MULTIVALENT IMMUNE LOBULINE
US20160289303A1 (en) 2013-11-15 2016-10-06 President And Fellows Of Harvard College Methods and compositions for the treatment of hcmv
US20180327482A1 (en) * 2013-11-15 2018-11-15 President And Fellows Of Harvard College Methods and compositions for the treatment of hcmv
CN106459182B (en) 2013-12-30 2021-09-03 岸迈生物科技有限公司 Tandem FAB immunoglobulins and uses thereof

Also Published As

Publication number Publication date
WO2022162097A3 (en) 2022-09-22
WO2022162097A2 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
IL289585A (en) Dll3-targeting antibodies and uses thereof
IL275826A (en) Anti-mct1 antibodies and uses thereof
EP4151652A4 (en) Anti-cd73 antibody and use thereof
EP4095160A4 (en) Anti-st2 antibody and application thereof
SG11202112112UA (en) Anti-galectin-9 antibodies and uses thereof
GB202017058D0 (en) Antibodies and uses thereof
IL291027A (en) Anti-steap1 antibodies and uses thereof
EP4139347A4 (en) Anti-cd3 antibodies and uses thereof
IL289656A (en) Anti-tigit antibodies and application thereof
IL287690A (en) Anti-hvem antibodies and use thereof
IL308808A (en) Anti-ccr8 antibodies and uses thereof
EP4095157A4 (en) Anti-angptl3 antibody and use thereof
IL291550A (en) Anti-il-27 antibodies and uses thereof
IL291546A (en) Anti-kir3dl3 antibodies and uses thereof
IL291280A (en) Anti-cd371 antibodies and uses thereof
EP4132974A4 (en) Anti-cd98 antibodies and uses thereof
IL307940A (en) Anti-adgre2 antibodies and uses thereof
IL307267A (en) Anti-cd122 antibodies and uses thereof
EP4153313A4 (en) Anti-sars-cov-2 antibodies and uses thereof
EP4169950A4 (en) Anti-lilrb1 antibody and uses thereof
IL286803A (en) Anti-tauc3 antibodies and uses thereof
EP4234580A4 (en) Nkg2a-targeting antibody and use thereof
EP4274851A4 (en) Anti-gprc5d monoclonal antibodies and uses thereof
EP4079758A4 (en) Semg2 antibody and use thereof
EP4051713A4 (en) Immunomodulatory anti-cd73 antibodies and uses thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)